9 completed, 7 recruiting, 5 unknown, 4 active not recruiting. 29 Phase 3, 6 Phase 2.
Follow Gastric Adenocarcinoma: new trials by email Literature Review of Gastric Adenocarcinoma trials Research Report on Gastric Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer ASP2138, Pembrolizumab, Oxaliplatin - Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 570 | 2026-07-28 | 2026-10-22 |
| Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma Alternative Postoperative Treatment Regimen, Original Treatment Regimen, Postoperative Observation - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 405 | 2026-06-01 | 2026-05-22 |
| JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma Injection JS107&Toripalimab& Oxaliplatin Injection& Capecitabine, Sintilimab& Oxaliplatin Injection& Capecitabine - Gastric Adenocarcinoma | Phase 3 | Recruiting | NingBo Junyan Hongshi Biosciences Co., Ltd | 600 | 2026-05-28 | 2026-06-29 |
| Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity Standard of Care Chemotherapy, Biospecimen Collection, Computed Tomography - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 148 | 2025-10-24 | 2026-10-05 |
| A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma BL-M07D1, Investigator's choice of chemotherapy - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 490 | 2025-09-24 | 2025-11-17 |
| A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients CAR T cells, Control - Gastric Adenocarcinoma | Phase 3 | Recruiting | Suzhou Immunofoco Biotechnology Co., Ltd | 150 | 2025-08-06 | 2025-10-23 |
| Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer ERAS-tubeless group, ERAS-tube group - Gastric Adenocarcinoma, Laparoscopic Gastrectomy | Phase 3 | Recruiting | Zuoyi Jiao | 454 | 2025-06-16 | 2025-12-17 |
| Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer Docetaxel, Oxaliplatin, Leucovorin - Gastric Cancer, Stomach Cancer | Phase 2 / Phase 3 | Recruiting | Ukrainian Society of Clinical Oncology | 150 | 2025-03-25 | 2025-05-06 |
| ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma ASKB589, Oxaliplatin, Capecitabine - Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 3 | Active not recruiting | AskGene Pharma, Inc. | 780 | 2024-01-25 | 2026-09-16 |
| Evaluating Novel Therapies in ctDNA Positive GI Cancers Atezolizumab, Bevacizumab - Colon Adenocarcinoma, Rectal Adenocarcinoma | Phase 3 | Active not recruiting | Georgetown University | 11 | 2023-03-29 | 2026-10-06 |
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) Evorpacept (ALX148), Trastuzumab, Ramucirumab - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | ALX Oncology Inc. | 127 | 2022-01-15 | 2025-08-07 |
| A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma AK104, Placebo - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Completed | Akeso | 610 | 2021-09-17 | 2025-11-19 |
| Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer Preoperative Chemotherapy, Surgery, Postoperative chemotherapy - Gastric Adenocarcinoma | Phase 3 | Terminated | University Hospital, Lille | 6 | 2021-08-25 | 2025-12-23 |
| Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer tucatinib, trastuzumab, ramucirumab - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Completed | Seagen Inc. | 17 | 2021-03-22 | 2025-01-22 |
| A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106) Sintilimab, Ramucirumab, Cisplatin - Gastric Adenocarcinoma | Phase 3 | Terminated | Innovent Biologics (Suzhou) Co. Ltd. | 36 | 2021-03-10 | 2023-03-02 |
| A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma CS1001 monoclonal antibody, CS1001 placebo, Oxaliplatin - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Completed | CStone Pharmaceuticals | 479 | 2019-03-28 | 2023-11-29 |
| Adujvant CT+CRT vs Adujvant CT After D2 Resection for Locally Advanced Proximal Gastric Adenocarcinoma Adjuvant Chemoradiotherapy, Adjuvant Chemotherapy - Gastric Adenocarcinoma | Phase 3 | Unknown | Zhejiang Cancer Hospital | 408 | 2019-03-11 | 2019-06-04 |
| Compare Neoadjuvant DOS Combined With Toripalimab Versus SOX Combined With Toripalimab in Locally Advanced Gastric Adenocarcinoma Docetaxel+Oxaliplatin+S-1+Toripalimab, Oxaliplatin+S-1+Toripalimab - Gastric Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | Peking University | 248 | 2018-06-28 | 2026-09-21 |
| A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer Rivoceranib, Placebo - Gastric Cancer, Gastric Adenocarcinoma | Phase 3 | Completed | Elevar Therapeutics | 460 | 2017-03-14 | 2022-07-08 |
| A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Ramucirumab, Paclitaxel, Placebo - Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 3 | Completed | Eli Lilly and Company | 440 | 2017-03-02 | 2022-06-14 |
Showing 20 of 29. Sign in to see all of them.
Stomach Neoplasms (8) · Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Carcinoma, Hepatocellular (1) · Colonic Neoplasms (1) · Gastrointestinal Neoplasms (1) · Neoplasm Metastasis (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Peritoneal Neoplasms (1) · Rectal Neoplasms (1)
Digestive System Diseases (10) · Digestive System Neoplasms (10) · Neoplasms by Site (10) · Gastrointestinal Diseases (9) · Neoplasms (9) · Gastrointestinal Neoplasms (8) · Stomach Diseases (8) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Abdominal Neoplasms (1) · Adenocarcinoma (1) · Colonic Diseases (1) · Colorectal Neoplasms (1) · Intestinal Diseases (1)
Oxaliplatin (8) · Capecitabine (6) · Fluorouracil (5) · Paclitaxel (4) · Ramucirumab (4) · Cisplatin (3) · Docetaxel (3) · Leucovorin (3) · pembrolizumab (3) · S 1 (combination) (2) · Trastuzumab (2) · ALX148 (1) · Bevacizumab (1) · Chemoradiotherapy, Adjuvant (1) · Chemotherapy, Adjuvant (1)
Merck Sharp & Dohme LLC (2) · ALX Oncology Inc. (1) · Akeso (1) · AskGene Pharma, Inc. (1) · Astellas Pharma Global Development, Inc. (1) · CStone Pharmaceuticals (1) · Chinese Academy of Medical Sciences (1) · ECOG-ACRIN Cancer Research Group (1) · Elevar Therapeutics (1) · Eli Lilly and Company (1) · Georgetown University (1) · Gilead Sciences (1) · Hospices Civils de Lyon (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Lin Chen (1)
China (15) · United States (7) · France (5) · South Korea (5) · Italy (4) · United Kingdom (4) · Australia (3) · Japan (3) · Spain (3) · Taiwan (3) · Belgium (2) · Czechia (2) · Germany (2) · Poland (2) · Romania (2)
Francesco Di Costanzo, MD (1) · Guillaume Piessen, MD,PhD (1) · Jiafu Ji, MD (1) · Jiafu Ji, Professor (1) · Jing Huang, M.D. (1) · JoAl Mayor, PharmD, BCOP (1) · John L. Marshall, MD (1) · Lin Shen, MD (1) · Maheswari Senthil (1) · Michelle Ubowski, PharmD (1) · Mykyta Pepenin, MD (1)
PMID 33792646, PMID 37037952, PMID 40117530, PMID 24628950, PMID 29880231, PMID 32880601, PMID 34363528, PMID 34468869, PMID 34626550, PMID 34717717, PMID 35101941, PMID 35657979, PMID 36533429, PMID 37399357, PMID 38589926, PMID 39843940, PMID 39992668, PMID 42786305
2015 (2), 2014 (1), 2025 (1), U10CA180820 (1)